These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
652 related articles for article (PubMed ID: 19433320)
1. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Koontz BF; Chino J; Lee WR; Hahn CA; Buckley N; Huang S; Kim J; Reagan R; Joyner R; Anscher MS Brachytherapy; 2009; 8(2):191-196. PubMed ID: 19433320 [TBL] [Abstract][Full Text] [Related]
2. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404 [TBL] [Abstract][Full Text] [Related]
3. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851 [TBL] [Abstract][Full Text] [Related]
4. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation. Baumann BC; Baumann JC; Christodouleas JP; Soffen E Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422 [TBL] [Abstract][Full Text] [Related]
5. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer. Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568 [TBL] [Abstract][Full Text] [Related]
6. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
7. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432 [TBL] [Abstract][Full Text] [Related]
8. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929 [TBL] [Abstract][Full Text] [Related]
9. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Vicini FA; Kestin LL; Martinez AA Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815 [TBL] [Abstract][Full Text] [Related]
10. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358 [TBL] [Abstract][Full Text] [Related]
11. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788 [TBL] [Abstract][Full Text] [Related]
12. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244 [TBL] [Abstract][Full Text] [Related]
13. A systematic overview of radiation therapy effects in prostate cancer. Nilsson S; Norlén BJ; Widmark A Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499 [TBL] [Abstract][Full Text] [Related]
14. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer. Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952 [TBL] [Abstract][Full Text] [Related]